Rebirth Strongest Tycoon

You can search “Rebirth Strongest Tycoon 妙笔阁novel website (imiaobige.com)” in Baidu to find the latest chapter!

In the venture capital circle of San Francisco, Genentech’s reputation is very loud. After all, it only took less than 4 years. Its valuation has soared from 400,000 USD to more than 100 million USD, and it is also on the track of listing. .

It can be said that if you do not know Dao Foundation Intek, you are not qualified to say that you are a practitioner in the venture capital industry.

But when Polaris Capital strongly acquired Genentech and the news of the suspension of the listing process came out, the whole circle was immediately shocked, and they asked for details.

When I learned that Polaris Capital had given the lowest valuation of 200 million USD, everyone was shocked by the great generosity of Polaris Capital.

Of course, there are also sour-hearted people who secretly satirize the brain damage of Polaris Capital, and unexpectedly pay such a high price.

But no matter what they think, at least one thing is certain.

Polaris Capital has rushed into this circle with an extremely powerful posture. All capital companies in San Francisco know that this market has another crocodile on a rampage.

What the outside world and colleagues thought, Xia Yu didn’t have the thought to care about it. After finishing the acquisition of Genentech, he told Peter Lynch to continue recruiting, and then he started the second operation.

Time is urgent, he must act quickly, lest the cake is eaten by others!

For his goal this time, he intends to come up with a big one that will make Polaris Capital’s reputation in one fell swoop, and at the same time lay a Heaven Supporting Pillar for his strategy in the biopharmaceutical field.

Genentech has the future.

It also cost him more than 100 million USD. According to this schedule, he wants to spend most of the money in his hands. I don’t know that time that will never come. Only one of the giants of biopharmaceuticals can digest it. a little.

This goal is the renowned Abbott company of the latter generation.

In the 80s, it was still the era of oil. Among the top ten companies in the United States, oil companies accounted for half of the country.

But in the 90 years, it will be the time when the biopharmaceutical field will explode.

At that time, it will be too late to enter the venue. It is definitely a suitable time to enter early.

Because nowadays, the biopharmaceutical field has not yet exploded. Even the giants in this industry have a low market value, and there is not even a 100 100000000 million USD level.

It is worth mentioning that the company with the highest market value in United States is the blue giant IBM with a market value of more than 300 and 100000000 million USD.

Back to the topic, let’s talk about the biopharmaceutical field.

At this time, there are many pharmaceutical giants in the United States. It is not Johnson & Johnson, which is the first in the later generation, but Merck, which has a market value of more than 2 and 1000 USD, and Johnson & Johnson is in second place.

Next, there are companies such as Eli Lilly, 100 Hour Myers Squibb, Pfizer, Wyeth, Abbott.

That’s right, although Pfizer is already strong at this time, it is not a later generation global pharmaceutical giant, and Wyeth has not been given Mergers and Acquisitions by Pfizer.

Among these companies, Xia Yu is eyeing Abbott, which is Ranked 9th in the pharmaceutical field of United States at this time.

Johnson & Johnson’s later generation has a market value of more than 3000 and 100000000 USD, which once exceeded 4 billion USD, and Pfizer is also hovering at 100 billion USD. It stands to reason that these two companies should have the greatest potential and should be the hunting targets.

But in fact, Xia Yu gave these two pass after considering it.

There is no way, behind Johnson & Johnson is the major consortium, he recruited cannot afford to offend. At this time, Johnson & Johnson is developing well, and the consortium, which is not bad for money, will not sell it.

As for Pfizer, the latter generation Viagra is popular all over the world, but it is still more than ten years before Viagra was developed.

Furthermore, Xia Yu also knows that the market value of Pfizer’s later generation is very high, but that high market value is piled up with huge capital. Pfizer’s ability to sit in that position depends entirely on mergers and acquisitions again and again. Viagra can’t hold this height.

The history of the rise of Pfizer is a history of mergers and acquisitions in the pharmaceutical field. Since 1999, Pfizer has acquired Warner Lambert, Pharmacia, and Wyeth with a large amount of money, and obtained a large number of high-quality brand-name drugs. It can be ranked in the top 10 in the history of pharmaceutical companies’ mergers and acquisitions, with a total value of 2441100000000 USD!

Among them, the acquisition of Warner Lambert was the largest acquisition in the history of pharmaceuticals before Xia Yu was reborn!

Leaving aside later generation, Pfizer is also immersed in diversification and cannot extricate itself from it. In the eyes of the outside world, Pfizer cannot be called a qualified pharmaceutical company.

Because Pfizer’s investment in scientific research is only 5%, far less than 100/9 of Merck and Johnson & Johnson.

Pfizer’s sinking lasted for ten years. It didn’t wake up until the lack of scientific research results and the shortcomings of new drugs became apparent, and reinvested in great generosity research and development of new drugs. Only then did it successfully launch 1998 Aike in 10000.

So at this time, Xia Yu doesn’t want to mess with Pfizer.

Pfizer, which has always been thinking about buying, buying and buying, will not necessarily accept his acquisition.

That being the case, why should he be thankless?

The time to come is still long, there will always be a suitable opportunity to do it again!

As for why other companies did not choose Abbott, they chose Abbott because, besides Johnson & Johnson, Abbott has the greatest potential!

Also in the second half of this year, George B. Latman Court Academecian, who worked for Abbott, will leave and set up Amgen, the 100 billion USD giant of the later generation, and Amgen is also one of the top ten pharmaceutical companies in the later generation United States. one.

Then in 2011, in the later generation, Abbott split up an AbbVie company internally, and its market value broke 100 billion USD after being listed separately, making it one of the top ten pharmaceutical companies in the United States.

As for Abbott itself, its market value is also more than 1000 USD 100000000. Before AbbVie, it was located in the 6th place among pharmaceutical companies in the United States.

Calculating carefully, Abbott, which has a market value of only 2 1.8 billion USD, has been able to create 3 companies with more than 100 billion USD due to it, occupying 3 positions among the top ten pharmaceutical companies in the United States.

If the three companies add up, their market value will surpass that of Johnson & Johnson, the strongest pharmaceutical company in later generation United States.

And these three companies do not rely on mergers and acquisitions like Pfizer to rise up, but develop step by step. Although mergers and acquisitions will be part of the way, they are mainly engaged in R&D and development.

The potential is not worse than that of Johnson & Johnson. The market value is now much lower than that of Johnson & Johnson. The point is that it is not controlled by the United States Ten Major Consortiums, and the acquisition difficulty is much lower than that of Johnson & Johnson.

Xia Yu don’t choose it unless you are stupid!

In addition to being awesome in the pharmaceutical field, Abbott is also very good in the field of milk powder. It is now one of the three giants in the United States milk powder market.

In the milk powder market in United States, the three giants from large to small are Wyeth Group, Abbott and Mead Johnson, and the next-tier is Garbo.

Wyeth Group has overwhelmed Abbott in the pharmaceutical field or in the milk powder field, but Xia Yu has not considered acquiring Wyeth Group.

In any industry, the difficulty and cost of acquiring Old Second are even smaller.

Strictly speaking of which, Abbott is not so much a pharmaceutical company as it is a healthcare company, because its products involve the fields of nutrition, drugs, medical devices, diagnostic instruments and reagents.

After determining the target, Xia Yu immediately convened a company executives meeting to form an acquisition team again to make an acquisition plan.

At the same time, considering the subsequent series of actions, the number of companies at this time is far from enough. Xia Yu once again urged Korn Ferry to hire Polaris Capital to hire mergers and The elite of acquisitions experience.

The acquisition of Abbott is a major task, but it is definitely not the only task!